A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE2, PHASE3

Enrollment: 68

Sponsor: Vanderbilt University Medical Center

Summary

This is a randomized, placebo-controlled trial of Dantrolene (N= 84 participants) to demonstrate the feasibility of using intravenous (IV) dantrolene to study the effect of RyR2 inhibition on cardiac electrophysiology, hemodynamics, and ventricular arrhythmia inducibility in patients with structural heart disease referred for Ventricular Tachycardia (VT) ablation. The investigators will also explore the pharmacokinetic/pharmacodynamic relationship of IV dantrolene and its short-term effect on specific cardiac electrophysiologic and hemodynamic parameters.

Eligibility Criteria

Inclusion Criteria: * Greater than or equal to 18 years of age * Able to give written informed consent * Referred for catheter-based VT ablation * Structural heart disease (cardiomyopathy or RV/LV scar) * Permanent pacemaker or implantable cardioverter defibrillator Exclusion Criteria: * Mechanical ventricular support (e.g. LVAD, ECMO) * NYHA class IV heart failure * LVEF \< 20% * Morbid obesity (BMI \> 40 kg/m2) * Severe renal insufficiency (GFR\

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04134845). StuddyBuddy aggregates publicly available trial information.